Antengene: We Like the Deal
This Insight recommends participating in the IPO of Antengene considering the proposed valuation and market opportunity.
284 Views
Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
463 Views
Remain Overweight EM Relative To EAFE
The MSCI EM index (local currency) remains in an uptrend and is testing all-time highs set in January 2018 near 65,800; as long as the index is...
359 Views
I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry
I-Mab was listed in the US on Jan 17th and returned 96% since listing. I-Mab has a highly differentiated two segments of products, including...
374 Views
Dada Nexus (达达集团) IPO Trading - Larger Deal Size with Decent Potential Upside
Dada Nexus (DADA US) raised US$336m at US$16 per share, the mid-point of its IPO price range. The number of ADS sold was upsized by about 27%, to...
480 Views